Foundation system

THE CHORIODEREMIA RESEARCH FOUNDATION CO-FINANCING EQUIPMENT TO SUPPORT RESEARCH ON RARE RETINAL EYE DISEASES

Jasleen Jolly, DPhil MSc BSc (Hons) MCOptom

The MAIA Microperimeter System is a vital resource for clinical trial measurement and study monitoring of choridemia-related eye disease

Dr. Jolly’s work is invaluable in ensuring the highest quality and accuracy of clinical trials for CHM therapies.

— Neal Bench, Chairman of the CRF Board of Directors

SPRINGFIELD, MA, UNITED STATES OF AMERICA, Aug. 18, 2022 /EINPresswire.com/ — The Choroideremia Research Foundation (CRF) is pleased to announce its latest research award to Jasleen Jolly, DPhil MSc BSc (Hons) MCOptom, Associate Professor, Vision and Eye Research Institute, Anglia Ruskin University in Cambridge, UK.

The award supports the purchase of a Microperimeter Macular Integrity Assessment (MAIA) system, which has become a vital resource for both clinical trial measurement and choroideremia progression monitoring (CHM ). It is now possible to assess, study and understand nyctalopia, or night blindness, which is usually the first symptom of CHM. Dr. Jolly has previously conducted work on the best parameters to use to optimize the conduct of microperimetry to ensure consistency and quality of test center results, as well as the study of analytical techniques. With this new equipment, she will continue her work to better understand the impact of early changes in scotopic, or low light, function in both people with CHM and carriers of CHM.

“Dr. Jolly’s work is invaluable in ensuring the highest quality and accuracy of clinical trials for CHM therapies,” said Neal Bench, Chairman of the Board of CRF.

For more information on all FRC-supported research studies, please visit curechm.org/research/

###

About Choroideremia
Choroideremia (CHM) is a rare inherited form of blindness affecting approximately 1 in 50,000 people. Due to its X-linked mode of transmission, males are most severely affected, with females typically suffering from visual impairment much lighter. Symptoms begin in early childhood, with night blindness and visual field restriction being the first noticeable effects, eventually progressing to complete blindness. It is estimated that 6,000 people in the United States and 10,000 in the European Union are affected by choroideremia. There are currently no approved treatments for choroideremia.

About the Choroideremia Research Foundation Inc.
The Choroideremia Research Foundation was founded in 2000 as an international fundraising and patient advocacy organization to stimulate research into CHM. Since its inception, the FRC has provided more than $2.5 million in research grants and is the largest financial supporter of CHM research in the world. CRF-funded research has led to the development of a CHM animal model, the preclinical production of gene therapy vectors currently in clinical trial, and the CRF Biobank which stores tissue and stem cell samples donated by CHM patients. . For more information visit www.curechm.org

Catherine Wagner
Choroideremia Research Foundation
+1 800-210-0233
[email protected]
Visit us on social media:
Facebook
Twitter
LinkedIn
Other